Loading organizations...
§ Private Profile · Beijing, China
Yuanxin Huibao is a technology company.
Yuanxin Huibao provides health insurance technology services, specializing in commercial insurance for major and chronic illnesses. It integrates special drug access, video consultations, and efficient claims investigation. The company employs an "insurance + medical care + pharmaceuticals" model, aiding insurers with product design, risk control, and customer acquisition.
Founded in 2015 by He Tao, Yuanxin Huibao operates under Beijing Yuanxin Technology Group. Its inception addressed fragmented healthcare, necessitating a unified platform. This created an integrated ecosystem connecting medical services, patients, pharmaceuticals, and insurers, streamlining the healthcare journey.
Yuanxin Huibao primarily serves insurance and reinsurance companies, enabling them to offer robust health protection products. Its vision focuses on delivering reliable medical and pharmaceutical services through integrated capabilities across the value chain, fostering more accessible and cohesive individual healthcare.
Yuanxin Huibao has raised $243.1M across 3 funding rounds.
Yuanxin Huibao has raised $243.1M in total across 3 funding rounds.
Yuanxin Huibao is a technology-driven healthcare and insurance company specializing in integrated health insurance services and digital health platforms. It builds products such as specialized drug insurance, city supplementary health insurance, and an AI-powered claims processing platform. The company serves insurance providers, patients, and healthcare stakeholders by streamlining insurance claims, enabling access to specialized medications, and offering online and offline medical consultation services. Yuanxin Huibao addresses the problem of complex, inefficient health insurance claims and limited access to specialized drugs, achieving rapid growth with over 3 million policies sold in three days for its flagship product and processing more than 5 million claims with 89% automation[1][3][5].
Founded in 2015 in Beijing by He Tao, Yuanxin Huibao emerged from a vision to leverage technology to improve healthcare insurance and pharmaceutical services. The company quickly gained traction by launching China's first specialized drug insurance product, "Yao Anxin," which set a record for policy sales. Early investments from top-tier venture capital firms such as Sequoia Capital, Qiming Venture Partners, and Tencent helped fuel its expansion. Over time, Yuanxin Huibao expanded its product portfolio to include provincial and city-level supplementary health insurance products and established partnerships with entities like Hainan Free Trade Port Boao Hope City, reflecting an evolving focus on integrating insurance with digital health services[1][2].
Yuanxin Huibao rides the global trend of digital transformation in healthcare and insurance, particularly the integration of AI and big data to optimize claims processing and patient access to medications. The timing is critical as healthcare systems worldwide seek cost-effective, scalable solutions to manage rising drug costs and insurance complexities. Market forces such as increasing demand for specialized drug coverage, government support for supplementary health insurance, and digital health adoption favor Yuanxin Huibao’s growth. The company influences the ecosystem by setting benchmarks for insurance product innovation and operational automation, encouraging broader adoption of technology-driven health insurance services in China and beyond[1][4].
Yuanxin Huibao is poised for continued expansion both domestically and internationally, leveraging AI and data analytics to deepen its insurance technology capabilities. Future trends shaping its journey include increased demand for personalized health insurance products, cross-border pharmaceutical access, and further digitalization of healthcare services. As it scales, Yuanxin Huibao’s influence may extend to shaping regulatory frameworks and industry standards for specialized drug insurance and automated claims processing, reinforcing its role as a leading innovator in health insurance technology[1][5].
Yuanxin Huibao has raised $243.1M across 3 funding rounds. Most recently, it raised $232.1M Series F in August 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 3, 2021 | $232.1M Series F | — | B Capital Group, CITIC Securities, HEL VED, Hongshan Capital Group (Sequoia Capital China), INCE Capital, Kunling Capital, OrbiMed, Springhill, UOB | Announced |
| Nov 1, 2019 | $4M Series A | — | Qiming Venture Partners | Announced |
| Jul 1, 2019 | $7M Series A | — | Qiming Venture Partners | Announced |
Yuanxin Huibao has raised $243.1M in total across 3 funding rounds.
Yuanxin Huibao's investors include B Capital Group, CITIC Securities, Hel Ved, Hongshan Capital Group (Sequoia Capital China), INCE Capital, Kunling Capital, OrbiMed, Springhill, UOB, Qiming Venture Partners.